Company Encyclopedia
View More
name
Quoin Pharmaceuticals
QNRX.US
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc.
1.813 T
QNRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies

    Quoin Pharmaceuticals Ltd. has successfully achieved target loading concentrations for its proprietary topical rapamycin delivery technologies, formulating a lotion with 4% w/w and a dermal patch with 5% w/w rapamycin. The company plans to manufacture clinical trial batches in Q4 2025, with testing starting in H1 2026 for conditions lacking FDA-approved treatments. This marks a significant milestone for Quoin’s topical rapamycin programs.

    Reuters·
    US
    QNRX
    +41.40%
    Reuters·
    US
    QNRX
    +41.40%

    Quoin Pharmaceuticals Reports Q3 2025 Financial Results

    Quoin Pharmaceuticals Ltd (QNRX) reported its Q3 2025 financial results, highlighting a net loss of $3.9 million, attributed to increased R&D expenses. The company secured a private placement financing of up to $105.3 million and appointed Sally Lawlor as CFO. Quoin received Orphan Drug Designation for QRX003 and is expanding its pediatric Netherton clinical program. The NETHERTON NOW campaign has garnered over 1.5 million views. With a strong cash position, Quoin is set to support operations into 2027 while advancing its clinical programs for rare diseases.

    Tip Ranks·
    US
    QNRX
    +41.40%
    Tip Ranks·
    US
    QNRX
    +41.40%

    Quoin Pharmaceuticals Ltd - Files For Offering Of Up To 10.05 Million Adss - SEC Filing

    Quoin Pharmaceuticals Ltd :QUOIN PHARMACEUTICALS LTD - FILES FOR OFFERING OF UP TO 10.05 MILLION ADSS - SEC FILING

    Reuters·
    US
    74907L409
    0.00%
    US
    QNRX
    +41.40%
    Reuters·
    US
    74907L409
    0.00%
    US
    QNRX
    +41.40%

    Quoin Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    QNRX
    +41.40%
    LB filings·
    US
    QNRX
    +41.40%

    Quoin Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    QNRX
    +41.40%
    LB filings·
    US
    QNRX
    +41.40%